本文選題：卵巢癌　切入點：細(xì)胞系　出處：《揚州大學(xué)》2014年碩士論文

【摘要】：目的：檢測MUC4、MUC16及HER2在卵巢癌細(xì)胞系中的表達(dá)情況,探索其與卵巢癌發(fā)生發(fā)展的關(guān)系,及其在卵巢癌早期診斷、治療和預(yù)后監(jiān)測中的作用和意義。 方法：對人卵巢癌SKOV-3細(xì)胞株、OVCAR-3細(xì)胞株、CAOV-3細(xì)胞株進(jìn)行細(xì)胞培養(yǎng)；應(yīng)用RT-PCR技術(shù)檢測人卵巢癌三種細(xì)胞中MUC4、MUC16及HER2mRNA水平的表達(dá)情況；采用細(xì)胞免疫熒光法及Westen Blot法檢測人卵巢癌三種細(xì)胞中MUC4、MUC16及HER2蛋白水平的表達(dá)情況。 結(jié)果：(1)RT-PCR檢測結(jié)果顯示：MUC4mRNA在人卵巢癌CAOV-3細(xì)胞中表達(dá)量最高,在OVCAR-3細(xì)胞中次之,在SKOV-3細(xì)胞中最低,差異無統(tǒng)計學(xué)意義(P0.05); MUC16mRNA在人卵巢癌OVCAR-3細(xì)胞中表達(dá)量最高,在CAOV-3細(xì)胞中次之,在SKOV-3細(xì)胞中表達(dá)量最低,差異具有統(tǒng)計學(xué)意義(P0.05); HER2mRNA在人卵巢癌CAOV-3細(xì)胞中表達(dá)量最高,在OVCAR-3細(xì)胞中次之,在SKOV-3細(xì)胞中表達(dá)量最低,在SKOV-3細(xì)胞和OVCAR-3細(xì)胞中表達(dá)量差異無統(tǒng)計學(xué)意義(P0.05),而在SKOV-3細(xì)胞和CAOV-3細(xì)胞、OVCAR-3細(xì)胞和CAOV-3細(xì)胞中差異具有統(tǒng)計學(xué)意義(P0.05)。 (2)細(xì)胞免疫熒光法和Westen Blot法檢測發(fā)現(xiàn)：MUC4蛋白在人卵巢癌SKOV-3細(xì)胞和OVCAR-3細(xì)胞中不表達(dá),在CAOV-3細(xì)胞中有表達(dá)；MUC16蛋白在人卵巢癌SKOV-3細(xì)胞、OVCAR-3細(xì)胞、CAOV-3細(xì)胞中均有表達(dá),并且在OVCAR-3細(xì)胞中表達(dá)最高,在CAOV-3細(xì)胞次之,在SKOV-3細(xì)胞中表達(dá)最低,差異具有統(tǒng)計學(xué)意義(P0.05); HER2蛋白在SKOV-3細(xì)胞、OVCAR-3細(xì)胞和CAOV-3細(xì)胞中均有表達(dá),且在CAOV-3細(xì)胞中表達(dá)最高,在OVCAR-3細(xì)胞次之,在SKOV-3細(xì)胞中表達(dá)最低,差異具有統(tǒng)計學(xué)意義(P0.05)。 結(jié)論：(1)MUC4及、MUC16及HER2與卵巢癌的發(fā)生發(fā)展有密切的關(guān)系,并可能成為卵巢癌治療的新靶點。 (2)CA125(MUC16)在早期和晚期卵巢癌中表達(dá)水平不同可能與其在不同類型卵巢癌中不表達(dá)或低表達(dá)有關(guān)。 (3)MUC4、MUC16及HER2在不同卵巢癌細(xì)胞系中表達(dá)水平不一,MUC4可能單獨或聯(lián)合CA125(MUC16)作為卵巢癌臨床診斷、病情監(jiān)測的輔助實驗室指標(biāo)。
[Abstract]:Objective: to detect the expression of MUC4, MUC16 and HER2 in ovarian cancer cell lines, and explore their relationship with the occurrence and development of ovarian cancer, and its role and significance in early diagnosis, treatment and prognosis monitoring of ovarian cancer.
Methods: the human ovarian cancer SKOV-3 cell line, OVCAR-3 cell line, CAOV-3 cell line was cultured; three MUC4 cells in human ovarian cancer detection using RT-PCR technology, the expression of MUC16 and HER2mRNA levels; using immunofluorescence method and Westen Blot method to detect three kinds of MUC4 cells in human ovarian carcinoma, the expression of MUC16 the HER2 and protein levels.
Results: (1) RT-PCR test results showed that: MUC4mRNA in human ovarian cancer cell CAOV-3 expression was the highest in OVCAR-3 cells in the second, the lowest in SKOV-3 cells, there was no statistically significant difference (P0.05); MUC16mRNA in human ovarian cancer cell OVCAR-3 expression was the highest in CAOV-3 cells of SKOV-3 expression was the lowest, the difference was statistically significant (P0.05); HER2mRNA in human ovarian cancer cell CAOV-3 expression was the highest in OVCAR-3 cells of the lowest expression in SKOV-3 cells, SKOV-3 cells and OVCAR-3 cells in the expression of the difference was not statistically significant (P0.05), and in SKOV-3 cells and CAOV-3 cells, the difference was statistically significant in OVCAR-3 cells and CAOV-3 cells (P0.05).
(2) to detect cell immunofluorescence method and Westen Blot method: the expression of MUC4 protein in human ovarian cancer SKOV-3 cells and OVCAR-3 cells, are expressed in CAOV-3 cells; MUC16 protein OVCAR-3 in human ovarian cancer SKOV-3 cells, cells were expressed in CAOV-3 cells, and the highest expression in the OVCAR-3 cells in CAOV-3 cells, in SKOV-3 cells was the lowest, the difference was statistically significant (P0.05); HER2 protein in SKOV-3 cells expressed in OVCAR-3 cells and CAOV-3 cells, and expressed in CAOV-3 cells, OVCAR-3 cells in the SKOV-3 cells was the lowest, the difference was statistically significant (P0.05).
Conclusion: (1) MUC4 and MUC16 and HER2 are closely related to the development and development of ovarian cancer, and may be a new target for the treatment of ovarian cancer.
(2) the difference in expression level of CA125 (MUC16) in early and late ovarian cancer may be associated with non expression or low expression in different types of ovarian cancer.
(3) MUC4, MUC16 and HER2 have different expression levels in different ovarian cancer cell lines. MUC4 may be alone or combined with CA125 (MUC16) as an auxiliary laboratory index for ovarian cancer clinical diagnosis and disease surveillance.

【學(xué)位授予單位】：揚州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 陳瑩;易建平;劉海燕;趙潔;;MUC4和HER2/neu在卵巢上皮性癌中的表達(dá)及臨床意義[J];廣西醫(yī)科大學(xué)學(xué)報;2012年02期

，

本文編號：1687375